Exploring the Potential of Eltrombopag: Room for More?
acute myeloid leukemia
eltrombopag
immune thrombocytopenia
myelodysplastic syndrome
poor graft function
severe aplastic anemia
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
03
2022
accepted:
06
05
2022
entrez:
9
6
2022
pubmed:
10
6
2022
medline:
10
6
2022
Statut:
epublish
Résumé
Since its introduction in clinical practice, eltrombopag (ELT) has demonstrated efficacy in heterogeneous clinical contexts, encompassing both benign and malignant diseases, thus leading researchers to make a more in-depth study of its mechanism of action. As a result, a growing body of evidence demonstrates that ELT displays many effects ranging from native thrombopoietin agonism to immunomodulation, anti-inflammatory, and metabolic properties. These features collectively explain ELT effectiveness in a broad spectrum of indications; moreover, they suggest that ELT could be effective in different, challenging clinical scenarios. We reviewed the extended ELT mechanism of action in various diseases, with the aim of further exploring its full potential and hypothesize new, fascinating indications.
Identifiants
pubmed: 35677428
doi: 10.3389/fphar.2022.906036
pii: 906036
pmc: PMC9168361
doi:
Types de publication
Journal Article
Langues
eng
Pagination
906036Informations de copyright
Copyright © 2022 Tarantini, Cumbo, Anelli, Zagaria, Conserva, Redavid, Specchia, Musto and Albano.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Haematologica. 2016 Dec;101(12):1443-1445
pubmed: 27903709
Haematologica. 2016 Dec;101(12):1479-1488
pubmed: 27515246
Blood. 2014 Mar 20;123(12):1818-25
pubmed: 24345753
Br J Clin Pharmacol. 2018 Nov;84(11):2673-2677
pubmed: 30032487
Drugs. 2021 Jul;81(11):1285-1305
pubmed: 34160821
J Transl Med. 2006 Feb 16;4:9
pubmed: 16480521
Int J Mol Sci. 2020 Dec 24;22(1):
pubmed: 33374151
Blood. 2019 May 9;133(19):2043-2055
pubmed: 30803992
Cell. 2018 Nov 29;175(6):1701-1715.e16
pubmed: 30449622
Int J Hematol. 2014 Oct;100(4):341-4
pubmed: 25212676
Thromb Haemost. 2014 Dec;112(6):1219-29
pubmed: 25209750
Blood. 2018 Dec 20;132(25):2629-2638
pubmed: 30305280
Semin Immunopathol. 2011 Sep;33(5):487-95
pubmed: 21136061
Lancet Haematol. 2019 Mar;6(3):e122-e131
pubmed: 30704923
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):457-466
pubmed: 30504346
Drug Metab Dispos. 2011 Sep;39(9):1734-46
pubmed: 21646437
Acta Haematol. 2017;137(2):66-72
pubmed: 28006767
Br J Haematol. 2014 Jun;165(6):865-9
pubmed: 24725224
Nat Commun. 2021 Feb 18;12(1):1134
pubmed: 33602934
Hematol Oncol Clin North Am. 2018 Aug;32(4):581-594
pubmed: 30047412
Clin Ther. 2012 Mar;34(3):699-709
pubmed: 22336488
Lancet Haematol. 2015 Oct;2(10):e396-7
pubmed: 26686035
Transfus Med. 2016 Jun;26(3):202-7
pubmed: 27046441
Blood. 2017 Dec 7;130(23):2527-2536
pubmed: 29042367
Biol Blood Marrow Transplant. 2012 Sep;18(9):1329-40
pubmed: 22326303
Haematologica. 2014 May;99(5):937-44
pubmed: 24463212
Stem Cells. 2009 Feb;27(2):424-30
pubmed: 19038790
Blood. 2010 Nov 25;116(22):4639-45
pubmed: 20688957
Blood. 2016 Aug 11;128(6):852-61
pubmed: 27281793
Front Immunol. 2020 Apr 15;11:586
pubmed: 32351502
Leuk Res. 2011 Mar;35(3):323-8
pubmed: 20688394
Oncotarget. 2021 Jul 06;12(14):1377-1387
pubmed: 34262648
Cell Cycle. 2011 May 15;10(10):1582-9
pubmed: 21478671
Thromb Res. 2012 Sep;130(3):415-9
pubmed: 22789125
PLoS One. 2015 Apr 27;10(4):e0126691
pubmed: 25915523
Thromb Res. 2013 Aug;132(2):196-201
pubmed: 23830211
Cell. 2021 Mar 4;184(5):1139-1141
pubmed: 33667367
Blood. 2017 Oct 26;130(17):1923-1933
pubmed: 28864815
Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234
pubmed: 27713092
Bone Marrow Transplant. 2021 Jan;56(1):4-6
pubmed: 32572137
Blood. 2019 Jun 13;133(24):2575-2585
pubmed: 30992268
PLoS One. 2018 Dec 3;13(12):e0208102
pubmed: 30507954
Biol Blood Marrow Transplant. 2019 Jul;25(7):1320-1324
pubmed: 30710685
N Engl J Med. 2018 Oct 25;379(17):1643-1656
pubmed: 30354958
Blood. 2018 May 24;131(21):2399-2402
pubmed: 29632023
Blood. 2010 Nov 18;116(20):4175-84
pubmed: 20733158
Lancet Haematol. 2018 Jan;5(1):e34-e43
pubmed: 29241762
Ther Adv Hematol. 2020 Aug 17;11:2040620720948743
pubmed: 32874483
Blood. 2012 Oct 18;120(16):3318-25
pubmed: 22859611
Am J Hematol. 2015 Mar;90(3):E40-3
pubmed: 25400215
N Engl J Med. 2012 Jul 5;367(1):11-9
pubmed: 22762314
Haematologica. 2019 Jun;104(6):1112-1123
pubmed: 31073079
Blood. 2009 Oct 29;114(18):3899-908
pubmed: 19710504
Bioessays. 2018 Nov;40(11):e1800063
pubmed: 30159904
Cell Rep. 2019 Feb 5;26(6):1627-1640.e7
pubmed: 30726743
Lancet Haematol. 2015 Oct;2(10):e417-26
pubmed: 26686043
Haematologica. 2020 May 21;105(12):2785-2794
pubmed: 33256377
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):450-456
pubmed: 30504345
Int J Mol Sci. 2021 Jun 27;22(13):
pubmed: 34199099
J Hematol Oncol. 2018 Aug 16;11(1):103
pubmed: 30115080
Ther Adv Hematol. 2018 Oct 04;9(10):309-317
pubmed: 30344993
Ther Adv Hematol. 2021 Mar 3;12:2040620721998126
pubmed: 33747425
Front Immunol. 2021 Jul 29;12:723544
pubmed: 34394131
Blood. 2012 Jul 12;120(2):386-94
pubmed: 22627766
Stem Cells. 2016 Apr;34(4):1123-33
pubmed: 26748484
Cancer Manag Res. 2019 Sep 06;11:8229-8238
pubmed: 31564981
Mod Pathol. 2012 Jan;25(1):65-74
pubmed: 21841770
Front Oncol. 2018 Dec 05;8:587
pubmed: 30568919
Bone Marrow Transplant. 2019 Aug;54(8):1346-1353
pubmed: 30679824
Cells. 2019 Dec 20;9(1):
pubmed: 31861948
Semin Oncol. 2011 Oct;38(5):667-72
pubmed: 21943673